Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant sacituzumab govitecan + pembrolizumab versus physician's choice in residual triple-negative breast cancer
2024-512279-10-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Invasive disease-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-512279-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512279-10-00.